Whether or not the world’s fastest-growing vaccine against the new novel corona virus will work will be decided in the next few weeks.
The trial of the vaccine on humans began last week at the University of Oxford in the UK, and now scientists say it will be known in six weeks whether the drug will work or not.
“A number of British citizens are now being given this experimental vaccine with the expectation that it will be effective, which will be determined in mid-June,” said John Bell, a professor of medicine at Oxford University.
Scientists at Oxford University are working on the vaccine with the expectation that they will provide one million doses for use by September.
To that end, the British government on Thursday announced a new partnership with Oxford University and AstraZeneca, aimed at introducing the vaccine to its immediate success.
Professor John Bell said the research team has done a great job so far.
“Hundreds of people have been vaccinated so far and we expect to know by mid-June whether it will work,” he said.
Read Also:TB vaccine trial against code 19 in US
He said the new partnership would help ensure that the vaccine could be introduced immediately if it works.
“Once we get permission from the regulators, we don’t want to go back and analyze how to prepare it on a large scale,” he said.
“We also want to make sure that the vaccine is available worldwide, so that people in developing countries can get it, where it is most needed, we have a partner for that purpose,” he added. We needed to be able to do such a great job, because the capacity of the UK is not so great, so we will work with AstraZenka to improve that capacity.
When asked if British citizens would be given top priority if the vaccine is successful, he said that about 30 million people at risk would be vaccinated in the first phase, but Oxford would not. The country will work with partners to ensure that it is readily available worldwide.
“We are very careful not to make vaccines unavailable between developed and developing countries,” he said.
He said the pharmaceutical company had shown great generosity in its offer, which meant that vaccines would be available and distributed at a lower cost.
AstraZeneca chief executive Pascal Soroit said the company would supply the vaccine at cost at the time of the outbreak and expected several vaccines to be available in several countries when needed.
“In June or July, we will have figured out how effective this vaccine is,” he said.
Earlier this week, monkeys tested positive for the vaccine, saying the coronavirus had been eradicated from the animals in 28 days, despite being infected with large amounts of the virus.
The experiments on the monkeys were carried out by US scientists at the Rocky Mountain Laboratory at the end of March.
For this purpose, six monkeys were given a vaccine developed by the Genes Institute and the Oxford Vaccine Group, and were subsequently exposed to a large number of corona viruses, which had previously infected other monkeys.
The monkeys in the study showed no signs of disease and were healthy 28 days later.
“This species of monkey is genetically very close to humans,” said Vincent Mونnster, head of the virus ecology unit at the Rocky Mountain Laboratory.
The trial on humans began on April 23 and is expected to end by September.
For the initial phase, 500 volunteers between the ages of 18 and 55 have been recruited.
The trial of 500 volunteers will continue till the middle of next month in which a total of 510 volunteers have been divided into 5 groups.
One of these groups will also receive a follow-up booster dose after using the vaccine for the first time.
Researcher Professor Sarah Gilbert said the technology used to develop the vaccine was already being used in 10 different treatments, but that different test groups from different countries were needed for the corona virus. In order to ensure accurate results, this infection is spreading very fast in every corner of the world.
The research team is also seeking additional funding for large-scale vaccine development as it seeks mass production after a six-month human trial.
The idea is that the vaccine has proved effective for humans and will begin production in the fall, during which a final trial of 5,000 people will be completed and medical workers can start using it by September. Is.
In fact, Oxford University is committed to developing one million doses of the vaccine by September.
It may seem impossible to develop a vaccine in such a short period of time, but the Oxford University team was already preparing for an epidemic like the corona virus.
To that end, they developed a genetically modified chimpanzee virus that is the basis of the new virus.
They hope to be able to incorporate a safe virus into a vaccine that could train the immune system to fight code 19.
The Oxford University vaccine is one of the few trials of human trials have entered the stage.
China is testing three different vaccines on humans, one of which has entered the second phase.
Similarly, in March in the United States, the Moderina company first started testing a vaccine on humans, while the trial of the vaccine of another company, Inouye, began earlier this month.
Vaccines are also being tested on humans in Germany.
According to the Arab broadcaster Al Jazeera, the vaccine, developed by the German company Biotech and the multinational pharmaceutical company Pfizer, was tested on humans this week and by April 30, 12 doses of the vaccine had been given to volunteers.
The vaccine has been dubbed BNT 162 and will be tested on a total of 200 volunteers between the ages of 18 and 55.
However, the vaccines are said to take one to one-and-a-half years to be developed and approved for use, but Chinese scientists are hopeful that the vaccine will be available to medical staff by September and the general public by next year. Will be able to use to prevent corona virus in the beginning.
In contrast, a research team from Oxford University claimed earlier this month that their vaccine would be ready by September.
Sarah Gilbert, a professor of vaccineology at Oxford University, told The Times of London that she was “80 per cent confident” that the vaccine developed by her team would work and be ready by September.
“No one can promise that this vaccine will work, but I am 80 percent confident that we will succeed,” he said.
Even if British scientists are able to develop and use the vaccine by September, experts say it will take several months to develop millions of doses of the vaccine.
Professor Sarah said talks were under way with the British government for funding and production would begin before the final results, which would give people immediate access to the vaccine.
“If all goes well, success is possible by the fall,” he said.